Enabling better care decisions for patients around the world.
Using data from a standard CT scan, the non-invasive HeartFlow Analysis creates a personalized 3D model of the coronary arteries and analyzes the impact that blockages have on blood flow.
Be a Thing of the Past
Today’s non-invasive diagnostic tests provide little explanation of chest pain, leading many patients to unnecessary invasive testing.
In fact, more than half of patients who undergo these invasive tests have no significant blockage.1
Enables clinicians to identify
significant coronary artery disease
and determine the optimal
Easy Clinical Adoption
- 1) Perform coronary CT scan This standard imaging method captures detailed pictures of the heart and its blood vessels. Coronary CT scans are performed at tens of thousands of facilities worldwide.
- 2) Upload data via secure connection Using industry-leading protocols and technologies at every step to ensure protection of patient data, the CT images are securely transferred to HeartFlow.
- 3) HeartFlow analyzes data Powerful, cutting-edge computing technology and deep clinical experience are combined to assess the impact that blockages have on blood flow.
- 4) HeartFlow delivers results via secure interface Analyses are returned to clinicians and are used, along with other available information, to provide a more complete picture of each patient’s heart health.
Sophisticated Analysis, Delivered Simply
- HeartFlow creates a personalized, digital 3D model of the arteries.
- Powerful computer algorithms solve millions of complex equations to assess the impact that blockages have on blood flow.
- The result is a color-coded map that aids clinicians in determining, vessel-by-vessel, if sufficient blood is reaching the heart.
Oops! We could not locate your form.
Sign Up for Updates
1 Patel, et al., N Engl J Med 2010; 362: 886-95.
2 / 3 Douglas et al. Clinical outcomes of fractional flow reserve by computed tomographic angiography-guided diagnostic strategies vs. usual care in patients with suspected coronary artery disease: the prospective longitudinal trial of FFRCT: outcome and resource impacts study. Eur Heart J. 2015;36(47):3359-67.
4 Douglas, et al. J Am Coll Cardiol 2016; 68:435-45.
5 Data on file. In the PLATFORM Trial, the mean one-year per-patient cost for the usual care strategy was $12,145 compared to the $8,127 cost for the HeartFlow-guided strategy, a cost reduction of 33 percent. Not reported in the study results, mean costs remained 26 percent lower among the HeartFlow-guided patients than among usual care patients ($9,036 vs. $12,145, p<0.0001) when factoring in the $1,500 cost of the HeartFlow Analysis.
6 Hlatky et al. Quality-of-Life and Economic Outcomes of Assessing Fractional Flow Reserve With Computed Tomography Angiography: PLATFORM. J Am Coll Cardiol. 2015;66(21):2315-23.